Trial Profile

Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Capecitabine
Indications Gastric cancer; Oesophageal cancer
Focus Biomarker; Therapeutic Use
Acronyms GastroLap

Most Recent Events

17 Jan 2020 This trial has been completed in Germany as per Eudra CT record
09 Sep 2016 Discrepancy in status. NCT reports as discontinued, Eudra reports as suspended and German Clinical Trial Register reports as active, no longer recruiting. Retained it as per NCT, as it is a reliable source.
24 Apr 2013 Planned end date changed from 1 Jul 2015 to 1 Oct 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com